首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
【24h】

Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.

机译:作为替加环素评估和监测试验的一部分,对来自法国,德国,意大利,西班牙和英国的生物之间的抗生素敏感性进行了比较分析。

获取原文
获取原文并翻译 | 示例
           

摘要

As part of the tigecycline evaluation and surveillance trial (TEST), bacterial isolates were collected from 39 centres in France, Germany, Italy, Spain and the UK between January 2004 and August 2006. Antimicrobial susceptibilities were determined according to CLSI guidelines. Italy had the highest rate of methicillin-resistant Staphylococcus aureus (36.4%), and was the only country to report vancomycin-resistant Enterococcus faecalis (8.6%). Tigecycline was the only agent to which all Gram-positive isolates were susceptible. For many of the Gram-negative organisms collected, antimicrobial susceptibilities were lowest among isolates from Italy and highest among isolates from Spain. The notable exception was Acinetobacter baumannii, where the poorest susceptibility profile was among isolates from Spain. For A. baumannii, MIC(90)s of imipenem varied from 1 mg/L for isolates in France and Germany to >/=32 mg/L for isolates from Italy and Spain. Tigecycline was the only agent to maintain an MIC(90) of
机译:作为替加环素评估和监视试验(TEST)的一部分,从2004年1月至2006年8月之间,从法国,德国,意大利,西班牙和英国的39个中心收集了细菌分离株。根据CLSI指南确定了抗菌药的敏感性。意大利的耐甲氧西林金黄色葡萄球菌比例最高(36.4%),并且是唯一报告耐万古霉素的粪肠球菌(8.6%)的国家。 Tigecycline是所有革兰氏阳性分离株均易感的唯一药物。对于收集的许多革兰氏阴性菌,抗菌素敏感性在意大利分离株中最低,而在西班牙分离株中最高。值得注意的例外是鲍曼不动杆菌,其中最弱的易感性是来自西班牙的分离株。对于鲍曼不动杆菌,亚胺培南的MIC(90)值从法国和德国分离株的1 mg / L到意大利/西班牙分离株的> / = 32 mg / L不等。替加环素是唯一针对所有五个国家/地区的分离物保持MIC(90)≤= 1mg / L的药物。替加环素对革兰氏阳性和革兰氏阴性分离株的体外活性可能使其在医院感染的治疗中有价值,包括由其他耐药菌引起的感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号